Home > Knowledge > Content
Sep 20, 2017

Tigecycline  is the first approved new intravenous injection of glycyl tetracycline  antibiotics with broad spectrum antimicrobial activity for the treatment  of gram-negative or positive pathogens, anaerobic organisms and  methicillin-resistant Staphylococcus aureus (MRSA)  and methicillin-sensitive Staphylococcus aureus (MSSA) caused by clA1,  DSSSI, tigecycline to the doctors to provide a new, can be in the early  stages of treatment when the cause is not yet clear when the choice of  wide antibiotics , And do not need to adjust the dose according to renal dysfunction, easy to use, every 12 hours to take once.